Neuren Pharmaceuticals

NEU.AXPhase 3

Melbourne, AustraliaFounded 2001neurenpharma.com

Neuren Pharmaceuticals is a public biotech company listed on the Australian Securities Exchange (ASX: NEU) that specializes in discovering and developing treatments for serious neurological disorders. Its primary achievement is the U.S. FDA approval and commercialization of trofinetide for Rett syndrome, a landmark event driven by a strategic partnership with Acadia Pharmaceuticals. The company's strategy involves leveraging its expertise in neurotrophic factors to expand its pipeline into other rare, high-need conditions with significant unmet medical needs.

Market Cap

$1.0B

Founded

2001

Employees

11-50

Focus

Biotech

NEU.AX · Stock Price

USD 11.47+7.52 (+190.38%)

Historical price data

AI Company Overview

Technology Platform

Development of synthetic analogs of endogenous neurotrophic peptides (e.g., IGF-1, GDNF) to promote synaptic repair and modulate neuroinflammation in serious neurological disorders.

Pipeline Snapshot

14 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
NNZ-2591 + Placebo	Phelan-McDermid Syndrome	Phase 3
NNZ-2566 + Placebo	Fragile X Syndrome	Phase 2
NNZ-2566 + Placebo	Rett Syndrome	Phase 2
NNZ-2591	Phelan-McDermid Syndrome	Phase 2
NNZ-2591	Angelman Syndrome	Phase 2

Funding History

Total raised: $5M

GrantUndisclosedUS Department of DefenseJun 15, 2018

IPO$5MUndisclosedJun 15, 2005

Opportunities

Significant opportunity exists in expanding the commercial footprint of DAYBUE™ internationally and exploring lifecycle management.

The parallel Phase 2 development of NNZ-2591 in four distinct syndromes de-risks the platform and creates multiple near-term value inflection points.

The neurotrophic platform could be expanded into more prevalent neurological conditions.

Risk Factors

Revenue is entirely dependent on the commercial performance of a partner company (Acadia).

The clinical pipeline (NNZ-2591) faces inherent Phase 2 trial failure risk across multiple studies.

The company's value is concentrated in a single approved product for an ultra-rare disease.

Competitive Landscape

Trofinetide is the first and only approved therapy for Rett syndrome, providing a strong first-mover advantage. For its pipeline indications, competition is primarily from symptomatic care and early-stage investigational therapies, positioning NNZ-2591 as a potential first-in-class treatment in multiple areas of high unmet need.

Publications

Patents

Pipeline